Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDeltex Medical Regulatory News (DEMG)

  • There is currently no data for DEMG

Issue of Equity

18 Jan 2024 17:01

RNS Number : 2057A
Deltex Medical Group PLC
18 January 2024
 

18 January 2024

 

Deltex Medical Group plc

("Deltex Medical", the "Company" or the "Group")

 

Issue of equity to satisfy equity-settled non-executive directors' fees

 

The Board of Deltex Medical (AIM: DEMG), announces the issue of 49,372,352 new ordinary shares of 1p each in the capital of the Company (the "Ordinary Shares"), at an issue price of 0.17 pence per new Ordinary Share (the "Issue Price"). The Issue Price represents the Company's closing mid-market price on 17 January 2024.

 

The new Ordinary Shares are being issued in order to satisfy the fees of certain current and former non-executive directors for the year ending 31 December 2023 ("Fee Shares"), as has been done in previous years.

 

A total of 12,941,176 Fee Shares will be issued to former non-executive director Mark Wippell and a total of36,431,176 Fee Shares will be issued to current non-executive directors as set out below:

 

Resultant holding post Fee Shares

Director

Current Ordinary Shares held

Fee Shares issued

Ordinary Shares held

As a percentage of the enlarged share capital on Admission

Nigel Keen

332,267,649

22,313,529

354,581,178

18.70%

Chris Jones

6,479,109

14,117,647

20,596,756

1.09%

 

Under the contract with Nigel Keen, he or the Company can opt to settle his fees (plus employer's national insurance) by the issue of new ordinary shares at the share price at the time of issue and the same applies to Chris Jones' and Ben Carswell's contracts for up to half of their fees. These share issues are expected to occur on an annual basis when permitted.

 

Application for admission to trading and total voting rights

 

Application has been made for 49,372,352 new Ordinary Shares to be admitted to trading on AIM, which is expected to take effect on or around 24 January 2024 ("Admission").

 

Following Admission, the Company's issued share capital will comprise 1,896,025,700 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

For further information, please contact:

 

Deltex Medical Group plc

01243 774 837

Nigel Keen, Chairman

 investorinfo@Deltexmedical.com

Andy Mears, Chief Executive

Natalie Wettler, Group Finance Director

Nominated Adviser and Broker

Allenby Capital Limited

020 3328 5656

 

Jeremy Porter / Vivek Bhardwaj (Corporate Finance)

info@allenbycapital.com

Tony Quirke / Stefano Aquilino (Sales & Corporate Broking)

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

PDMRs:

Nigel Keen

Non-Executive Director - Chairman

Chris Jones

Non-Executive Director

 

 

2. 

Reason for the Notification

a)

Position/status

See 1a) above

b)

Initial notification/Amendment

Initial Notification

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Deltex Medical Group Plc

b)

LEI

213800XN34P6LI8J6M39

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary shares of 0.1p each in Deltex Medical Group Plc

 

Identification code

ISIN: GB0059337583

b)

Nature of the transaction

Fee shares

c)

Price(s) and volume(s)

Name

Price(s)

Volume(s)

Nigel Keen

0.17p

22,313,529

Chris Jones

0.17p

14,117,647

d)

Aggregated information:

- Aggregated volume

36,431,176

- Price

0.17p

e)

Date of the transaction

18 January 2024

f)

Place of the transaction

Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESFUFMAELSEIF
Date   Source Headline
20th Aug 20087:00 amRNSNHS National Technology Adopt
31st Jul 20088:29 amRNSTotal Voting Rights
8th Jul 20087:40 amRNSTrading Statement
1st Jul 20082:25 pmRNSDirector/PDMR Shareholding
30th Jun 20083:35 pmRNSTotal Voting Rights
30th Jun 20087:40 amRNSDirector/PDMR Shareholding
30th Jun 20087:30 amRNSDirector/PDMR Shareholding
30th Jun 20087:00 amRNSInterim Trial Results
26th Jun 20083:46 pmRNSIssue of Equity
24th Jun 200811:08 amRNSIssue of Equity
27th May 20084:00 pmRNSIssue of Equity
13th May 200811:50 amRNSResult of AGM
13th May 200811:50 amRNSResult of AGM
9th May 20089:22 amRNSHolding(s) in Company
8th May 20087:01 amRNSCardioQ-ODM Update
25th Apr 20089:07 amRNSClinical Paper
23rd Apr 20087:01 amRNSNext Generation of CardioQ
22nd Apr 200812:10 pmRNSHolding(s) in Company
18th Apr 20087:00 amRNSCompletion of Funding Package
15th Apr 20087:01 amRNSCardioQ update
14th Apr 20087:01 amRNSCardioQ update
7th Apr 20087:01 amRNSFinal Results
7th Apr 20087:01 amRNSNew Non-Executive Director
3rd Apr 20087:00 amRNSCardioQ update
2nd Apr 20087:01 amRNSCardioQ update
28th Mar 20087:02 amRNSNTAH update
26th Mar 20087:02 amRNSCardioQ update
20th Mar 20087:00 amRNSNotice of Results
3rd Mar 20083:22 pmRNSODM meta - analysis
25th Jan 20083:58 pmRNSDirector/PDMR Shareholding
23rd Jan 20087:01 amRNSPositive Scientific Review
23rd Jan 20087:01 amRNSPre-close update
18th Jan 200811:41 amRNSHSJ Article
26th Nov 20079:03 amRNSDirector/PDMR Shareholding
21st Nov 20077:02 amRNSCardioQ Product Endorsement
31st Oct 20072:15 pmRNSTotal Voting Rights
22nd Oct 20079:01 amRNSHolding(s) in Company
16th Oct 20074:03 pmRNSAdditional Listing
1st Oct 20077:06 amRNSCardioQ announcement
25th Sep 200711:00 amRNSInterim Results - Replacement
25th Sep 20077:03 amRNSInterim Results
16th Aug 20073:53 pmRNSAIM Rule 26 Information
31st Jul 20073:29 pmRNSTotal Voting Rights
25th Jul 200711:30 amRNSRecommendation for CardioQ
11th Jul 20077:01 amRNSTrading Statement
5th Jul 20073:30 pmRNSImproving Surgical Outcomes
29th Jun 20073:34 pmRNSDirector/PDMR Shareholding
29th Jun 20073:26 pmRNSAdditional Listing
29th Jun 20078:52 amRNSTotal Voting Rights
28th Jun 20077:04 amRNSNew Clinical Evidence

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.